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Abstract
Background & Aims: Acute-on-chronic liver failure (ACLF) is characterized by acute 
decompensation of cirrhosis (AD), organ failure(s) and high risk of short-term mortal-
ity with bacterial infection frequently as precipitating event. Innate immune pattern 
recognition receptors and members of the lectin pathway of complement activation 
are crucial to the innate immune response to pathogens. The aim of this study was to 
investigate whether single nucleotide polymorphisms (SNPs) of innate immune com-
ponents are associated with the occurrence of bacterial infections or mortality in 
patients with cirrhosis hospitalized for AD or ACLF.
Methods: Twenty-one innate immunity SNPs with known functional implica-
tions were genotyped in 826 AD/ACLF patients included in the CANONIC study. 
Associations between baseline characteristics of the patients, the occurrence of bac-
terial infections and survival rate at 90 days of follow-up in relation to the innate 
immunity genetic variants were analysed.
Results: The NOD2-G908R genetic variant was associated with mortality (HR 2.25, 
P = .004) independently of age and MELD Score. This association was also found in a 
predefined subgroup analysis in patients with bacterial infections (HR 2.78, P < .001) 
along with MBL_Yx (HR 1.72, P = .008) and MASP2_371 (HR 1.67, P = .012) genetic 
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1  | INTRODUC TION
Acute-on-chronic liver failure (ACLF) is a syndrome character-
ized by acute decompensation (AD) of a patient with cirrhosis, 
combined with the development of multi-organ failure and a high 
short-term mortality rate.1 Bacterial infections are considered the 
most frequent potential precipitating events in ACLF along with 
active alcoholism within the last 3 months and gastrointestinal 
haemorrhage. Bacterial infections are more frequently present 
in patients with ACLF as compared to patients with ‘mere’ AD of 
chronic liver disease (32.6% vs 21.8%, P < .001).1 This higher fre-
quency of bacterial infections in patients with ACLF was because 
of a higher prevalence of spontaneous bacterial peritonitis (SBP) 
(10.6% vs 5.6%; P < .01) and pneumonia (6.1% vs 2.2%; P < .01). 
Bacterial infections are known to be associated with poorer clinical 
course and higher mortality in patients with ACLF.2 Host defense 
mechanisms are impaired in patients with cirrhosis. Bacterial trans-
location, defined as the migration of bacteria or bacterial products 
from the intestinal lumen to mesenteric lymph nodes,3 and the hy-
perdynamic circulatory state have been postulated to be key fac-
tors in the pathogenesis of infections in cirrhosis.4 Gut microbiota, 
alterations in the intestinal mucosal barrier and innate immunity, 
the antigen nonspecific immune function, are all involved in bacte-
rial translocation.5,6
The lectin pathway is part of the complement activation cascade 
in which molecules function as pattern recognition molecules to 
active processes of innate immunity. Lectins include ficolins (FNCs) 
and mannan-binding lectin (MBL) which are mainly produced by the 
liver.7 FNCs are a group of oligomeric lectin proteins which recog-
nize components of bacterial or fungal cell walls.8,9 MBL-associated 
serine proteases (MASP) can form complexes with MBL and FNCs, 
leading to activation of the lectin pathway, involving C3b-mediated 
opsonization of the pathogen and formation of the membrane attack 
complex.10 Various single nucleotide polymorphisms (SNPs) in innate 
immunity genes with functional implications on protein levels have 
been described. Polymorphisms in the MBL2 gene, for instance, are 
known to affect proper lectin composition and impair its activity.11-13 
In patients with cirrhosis, deficiency in MBL protein serum levels is 
reported to be associated with an increased risk of and shorter time 
to developing bacterial infection.14 Low levels of serum ficolin were 
found to be associated with a higher risk of occurrence of cirrho-
sis-associated bacterial infections.15
Multiple other components are also involved in innate immune 
system signalling against pathogens, such as Toll-like receptor 2 
(TLR2), Toll-like receptor 4 (TLR4), myeloid differentiation factor 88 
(MYD88) and nucleotide-binding oligomerization domain 2 (NOD2). 
NOD2 and TLR receptors are involved in the intracellular recogni-
tion of bacterial pathogens and therefore are of key importance in 
the innate immune system. It is yet undefined whether SNPs with 
known functional implications in these innate immunity components 
are associated with bacterial infections or mortality in patients with 
decompensated cirrhosis or ACLF. In this study, we aimed to assess if 
functionally relevant polymorphisms in the lectin complement path-
way and innate immune signalling components for pathogen recog-
nition contribute to the susceptibility to bacterial infections and risk 
of mortality in cirrhotic patients hospitalized for AD or ACLF.
2  | PATIENTS AND METHODS
2.1 | Study design
This study was performed as part of the CLIF Acute-on-chronic 
liver failure in cirrhosis (CANONIC) study, a prospective, observa-
tional, multicentre study aimed at identifying the diagnostic crite-
ria of ACLF and to describe the development of this syndrome in 
European patients with AD.1 Between February and September 
Key points
• Patients with cirrhosis, a chronic liver disease, have fre-
quent bacterial infections.
• MASP, MBL and NOD2 genes have an important func-
tion in the immune system.
• In this study we found that patients with an infection 
and specific genetic variants in those genes had a higher 
risk of dying after 90 days.
variants. None of the analysed SNPs were significantly associated with the occur-
rence of acute bacterial infections or spontaneous bacterial peritonitis in particular.
Conclusions: Innate immune system-specific NOD2-G908R, MBL_Yx and MASP2_371 
genetic variants were independently associated with increased risk of short-term 
mortality in AD/ACLF patients with bacterial infection.
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2011, 1349 patients with cirrhosis hospitalized for AD were in-
cluded in 29 hospitals in eight European countries. All 826 patients 
who gave informed consent for isolation and storage of DNA for 
future research with DNA available were included in this study. 
This study was performed in accordance with the Declaration of 
Helsinki and approved by the ethics committees of all participat-
ing centres.
Data from time of enrolment concerning demographic and clinico-
pathological characteristics of the patients, laboratory measurements 
(INR, white blood cell [WBC], CRP) and clinical scores (Child-Pugh 
score, MELD score, CLIF-organ failure score) were retrieved from the 
CANONIC study database. Patients were followed until death, liver 
transplantation or end-of-follow-up 3 months following the date of 
inclusion. AD was defined as an acute development of one or more 
complications of chronic liver disease. ACLF and individual organ fail-
ures were defined using the CLIF-Organ Failure score.16 The definition 
of acute bacterial infection included SBP, spontaneous bacteraemia, 
urinary tract infection, pneumonia and cellulitis as well as every other 
type of acute bacterial infection diagnosed at baseline hospital admis-
sion or during the 3-month follow-up period.
2.2 | Genotype determination
Twenty-one genetic variants in the MBL2, FCN2, MASP2, TLR2, TLR4 
and NOD2 genes with known functional implications on protein level 
were evaluated.17-20 Genomic DNA was extracted from 10 mL EDTA 
peripheral blood samples. Genotype identification was performed at 
the Leiden University Medical Centre, Leiden, The Netherlands. All 
genotypes were analysed using High-Resolution Melting Analysis 
(HRMA) with oligonucleotide primers, deoxyribonucleotide triphos-
phates (dNTPs), polymerase chain reaction (PCR) buffer FS-Taq 
Polymerase and specific probe in the presence of fluorochrome LC-
green Plus. Detailed description of genotyping and assessment has 
been published previously.17,18 DNA fragments were visualized using 
a Idaho Technology Lightscanner. HRMA genotyping of NOD2 was not 
conclusive (data not shown), therefore it was performed with Biorad 
Realtime thermal cycler CFX96 with Precision Melt Analysis Software 
with oligonucleotide primers (Table S1) in the presence of SsoFast 
EvaGreen Supermix. All found genetic variants were validated by DNA 
sequencing. The investigators were blinded for clinical outcomes dur-
ing genotype determination. European cohort minor allele frequen-
cies of the 1000 Genome Project were used as reference of genetic 
variation.21
2.3 | Statistical analysis
Associations between baseline characteristics of the patients, fol-
low-up data and tested genetic variants were analysed by using the 
Mann-Whitney U test, Student's t test or Chi-square test when ap-
propriate. The chi-squared test for Hardy-Weinberg equilibrium was 
used to evaluate the deviation of equilibrium. Multivariate logistic 
regression was used to evaluate the association between genetic vari-
ants and the occurrence of bacterial infection. Univariate and multi-
variate competing risks proportional hazards regression analysis was 
performed for prognostic factors of mortality using the method of 
Fine and Gray22 with liver transplantation as competing risk event. 
Univariate parameters were included at the P = .20 level and results 
with P ≤ .05 were considered to be statistically significant. The prob-
ability of survival within 90 days of follow-up according to the genetic 
variants was determined with cumulative incidence curves.
3  | RESULTS
3.1 | Patient population
Clinical data and DNA samples were available for 826 patients with 
decompensated cirrhosis included in the CANONIC study. Within this 
group, 185 patients were diagnosed with ACLF at study enrolment and 
78 patients developed ACLF during the follow-up period. Univariate 
analysis showed no association between individual SNPs and occur-
rence or grade of ACLF, therefore in the analyses no distinction was 
made between patients with ACLF or AD alone. Baseline clinical char-
acteristics of all patients are shown in Table 1. Mean age was 57.6 years 
and gender was predominantly male (63.6%). Main aetiologies of cir-
rhosis were alcoholic liver disease (60%) and hepatitis C (32.4%). The 
majority of patients had ascites at the time of inclusion in this study 
(89.7%). Patients with acute bacterial infection had higher baseline lev-
els of CRP, WBC and clinical disease score (MELD score 21.6 vs 16.6, 
P < .001 and CLIF-C OF score 8.5 vs 7.1, P < .001). Previous prophy-
lactic antibiotic use for SBP was lower in patients with acute bacterial 
infection (15.6% vs 9.7%, P = .016). In Table S2, genotypes and allele 
frequencies are shown for all genotyped SNPs. Minor allele frequen-
cies of all analysed genetic variants were comparable to previously 
reported frequencies of the European cohort in the 1000 Genome 
Project.21 In some cases, available DNA quantity was not sufficient to 
obtain complete genotype for all polymorphisms. All allele frequencies 
were in Hardy-Weinberg equilibrium, except for MBL2_HL (P = .008), 
MASP2_371 (P = .008) and MD2_157 (P < .001). A homozygous NOD2 
mutation was not detected in any patient. For 22 patients no informa-
tion about the presence or absence of bacterial infection was available.
3.2 | Innate immunity genetic variants are 
associated with increased mortality
Univariate analysis between genetic variants and mortality showed 
that patients with a NOD2-G908R genetic variant had a signifi-
cantly higher risk of mortality at 90 days of follow-up as compared 
to wildtype profile (5.7% vs 2.2%, P = .028), whereas patients with 
NOD2-R702W and NOD2-L1007FSINSC genetic variants showed 
no relation with decreased survival (Table 2). Multivariate analysis 
for mortality at 90 days in all patients (n = 812) showed that NOD2-
G908R (OR 2.25, P = .004) was the strongest predictor of mortality 
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with liver transplantation as competing risk, along with age (HR 1.03, 
P < .001) and MELD score (HR 1.15, P < .001). In a predefined sub-
group analysis in patients who developed acute bacterial infection at 
baseline or during 3 months after inclusion (n = 331), heterozygous 
genetic variants of NOD2-G908R (8.0% vs 0.9%, P = .002), MASP_371 
(42% vs 25.8%, P = .012) and MBL_Yx (42.2% vs 31.8%, P = .056) were 
associated with increased mortality after 90 days of follow-up in com-
parison to the wildtype profile (Table 3). In a competing risk propor-
tional hazards model, NOD2-G908R (HR 2.78, P < .001), MASP2_371 
(HR 1.67, P < .012) and MBL_Yx (HR 1.72, P < .008) genetic variants 
were associated with worse survival at 90 days, independently of age 
and MELD score (Figures S1 and S2).
Variable
Presence of bacterial infection
P-value




Age (y) 58.3 ± 11.79 56.7 ± 11.90 .072
Male gender 314/473 (66.4%) 199/331 (60.1%) .069
Aetiology of cirrhosis
Alcoholic liver disease 284/468 (60.7%) 191/327 (58.4%) .520
HCV 135/447 (30.2%) 112/315 (35.6%) .120
HBV 22/446 (4.9%) 17/313 (5.4%) .759
Other 98/449 (21.8%) 57/319 (17.9%) .178
Clinical features
Alcoholic hepatitis 4/445 (0.9%) 6/322 (1.9%) .245
Ascites 406/473 (85.8%) 314/331 (94.9%) <.001
Hepatic encephalopathy 132/473 (27.9%) 134/331 (40.5%) .002
Gastrointestinal bleeding 84/473 (17.8%) 42/331 (12.7%) .052
Organ failures
Liver 48/473 (10.1%) 63/331 (19.0%) .003
Kidney 21/473 (4.4%) 80/331 (24.2%) <.001
Cerebral 7/473 (1.5%) 40/331 (12.1%) <.001
Coagulation 23/473 (4.9%) 38/331 (11.5%) .005
Respiratory 4/473 (0.8%) 14/331 (4.2%) .001
Circulatory 4/473 (0.8%) 28/331 (8.5%) <.001
Treatments
Nonselective betablockers 39/461 (8.5%) 38/319 (11.9%) .112
Prophylactic antibiotic for SBP 72/461 (15.6%) 31/320 (9.7%) .016
Rifaximin 12/460 (2.6%) 22/319 (6.9%) .004
Laboratory data
INR 1.41 (1.26-1.70) 1.60 (1.39-2.05) <.001
CRP 13.00 (5.00-25.50) 30.40 (13.00-56.00) <.001
WBC 5.49 (3.88-8.04) 6.94 (4.80-10.80) <.001
Platelet count 92.00 (58.00-144.00) 77.00 (52.00- 119.00) .001
Bilirubin 2.70 (1.50-5.60) 4.20 (1.90-9.06) <.001
Creatinine 0.90 (0.70-1.20) 1.11 (0.80-1.87) <.001
Clinical scores
Child-Pugh 9.0 ± 1.93 10.3 ± 2.18 <.001
MELD 16.6 ± 5.84 21.6 ± 8.11 <.001
CLIF-C OF 7.1 ± 1.23 8.5 ± 2.37 <.001
Abbreviation: ACLF, acute-on-chronic liver failure; AD, acute decompensation; CLIF-C OF, chronic 
liver failure organ failure score; CRP, C-reactive protein; HCV, hepatitis C virus; HE, hepatic 
encephalopathy; INR, international normalized ratio; MAP, mean arterial pressure; MELD, model 
for end-stage liver disease; SBP, spontaneous bacterial peritonitis; WBC, white blood cell.
TA B L E  1   Baseline characteristics of 
entire cohort of patients with AD or ACLF
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3.3 | Acute bacterial infection
Two hundred patients (24.9%) were admitted to the hospital with 
bacterial infection at baseline and 131 additional patients were di-
agnosed with a bacterial infection during the 3-month follow-up pe-
riod. Of all bacterial infections during the study period, 78 (23.6%) 
were SBP. None of the individual functional polymorphisms were 
significantly associated with the occurrence of acute bacterial in-
fections or SBP in particular (Table S3). In Table 4, genetic variants 
in relation to bacterial infections with P ≤ .20 in univariate analysis 
are presented. In multivariate analysis, CLIF-C OF score (OR 1.61, 
P < .001) and WBC (OR 1.07, P < .001) were significantly associated 
with bacterial infection. Prophylactic antibiotic use for SBP during 
the whole study period showed a significant reduced risk for bacte-
rial infection (OR 0.45, P = .004).
3.4 | NOD2-G908R, MASP2_371 and MBL_Yx  
haplotype
Three hundred and fifteen patients (38.7%) had no genetic variant of 
NOD2-G908R, MASP2_371 or MBL_Yx. Three hundred and sixty-
nine patients (45.3%) had one genetic variant present and 130 pa-
tients (16%) had two or more genetic variants. In univariate analysis, 
patients with a haplotype of one, or two or more genetic variants 
had a significantly increased mortality rate at 28 days (respectively 
11% and 17% vs 7%, P = .001) and 90 days (21% and 25% vs 17%, 
P = .038) (Table S4). In a predefined subgroup analysis of patients 
with a bacterial infection (n = 326) and a haplotype of one, or two 
or more genetic variants, mortality was even higher as compared to 
patients without genetic variants at 28 days (respectively 24% and 
33% vs 10%, P < .001) and 90 days (37% and 44% vs 20%, P < .001) 
(Table S5). In a competing risk proportional hazards model, a hap-
lotype with one genetic variant (HR 2.27, CI 1.44-3.56, P < .001) 
and a haplotype of two or more genetic variants (HR 2.64, CI 1.51-
4.62, P < .001) were associated with worse survival in patients with 
bacterial infection at 90 days, independently of age or MELD score 
(Figure 1).
In patients without bacterial infection with at least one genetic 
variant (n = 466), mortality was not increased as compared to pa-
tients without genetic variants at 28 days (3% vs 4%, P = .289) and 
90 days (9% vs 14%, P = .088). There was no association between 
haplotype genetic variants and occurrence of bacterial infection in 
all patients (OR 1.12, CI 0.84-1.50, P = .443).
4  | DISCUSSION
Bacterial infections are among the most frequent precipitating events 
in patients with ACLF in Western countries and are associated with 
systemic inflammation, poor clinical course and high mortality rate.2 
TA B L E  2   Univariate and multivariate analysis - mortality of all patients after 90 days
Univariate analysis Multivariate analysis
 Alive Dead P-value  HR (95% CI) P-value
MASP2_120 (TT) 618/652 (94.8%) 146/160 (91.3%) .089 Age 1.03 (1.02-1.05) <.001
MASP2_120 (TC) 34/652 (5.2%) 14/160 (8.8%)  MELD score 1.15 (1.12-1.17) <.001
FCN2B_6359 (CC) 344/655 (52.5%) 69/160 (43.1%) .103 NOD2_G908R  
(GC vs GG)
2.25 (1.30-3.91) .004
FCN2B_6359 (CT) 256/655 (39.1%) 75/160 (46.9%)    
FCN2B_6359 (TT) 55/655 (8.4%) 16/160 (10.0%)    
MASP2_371 (AA) 424/651 (65.1%) 97/158 (61.4%) .192   
MASP2_371 (AC) 186/651 (28.6%) 55/158 (34.8%)    
MASP2_371 (CC) 41/651 (6.3%) 6/158 (3.8%)    
MBL_haplotype (A) 561/649 (86.4%) 129/159 (81.1%) .089   
MBL_haplotype (B) 88/649 (13.6%) 30/159 (18.9%)    
MYD_88 (AA) 444/658 (67.5%) 117/160 (73.1%) .168   
MYD_88 (AG/GG) 214/658 (32.5%) 43/160 (26.9%)    
NOD2_R702W (CC) 582/651 (89.4%) 148/158 (93.7%) .105   
NOD2_R702W (CT) 69/651 (10.6%) 10/158 (6.3%)    
NOD2_G908R (GG) 636/650 (97.8%) 149/158 (94.3%) .028   
NOD2_G908R (GC) 14/650 (2.2%) 9/158 (5.7%)    
NOD2_L1007FSINSC (GG) 612/651 (94.0%) 153/158 (96.8%) .160   
NOD2_L1007FSINSC (GC) 39/651 (6.0%) 5/158 (3.2%)    
Note: In univariate analysis only SNPs with P-value < .2 are presented, which were included in the multivariate analysis. Liver transplantation as 
competing risk in multivariate analysis of mortality. Age and MELD score were taken as independent variables.
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We hypothesized that identification of genetic factors predisposing 
to systemic infections or mortality in cirrhosis could contribute to 
better preventive strategies and potential improvement of outcome 
in cirrhotic patients hospitalized for AD or ACLF. Such an approach 
might in time contribute to personalized treatment protocols, aiming 
to reduce bacterial infections as potential precipitating events of AD 
or ACLF and ultimately improved survival.
In this study we assessed the association between single nucleotide 
polymorphisms (SNPs) in the lectin complement pathway and innate 
immune signalling components for pathogen recognition and the occur-
rence of bacterial infections or mortality in patients with cirrhosis hospi-
talized for AD or ACLF. We found that patients with bacterial infection 
and individually or combined NOD2-G908R, MASP2_371 and MBL_Yx 
genetic variants had a significantly higher risk of mortality during the 
study period as compared to patients with a wildtype profile. None of 
the analysed genetic variants were significantly associated with the oc-
currence of acute bacterial infections in general or SBP in particular.
Bacterial translocation and activation of the innate immune re-
sponse play important roles in the development of AD in patients 
with cirrhosis.5 Innate pattern recognition receptors such as NOD2 
receptors are involved in the recognition and clearance of bacterial 
pathogens and the presence of genetic alterations in these recep-
tors may cause impaired immune function and increased bacterial 
translocation.23,24 The association between NOD2 genetic variants 
TA B L E  3   Univariate and multivariate analysis - mortality in patients with bacterial infection after 90 days
Univariate analysis Multivariate analysis
 Alive Dead P-value  HR (95% CI) P-value
MASP2_120 (TT) 209/221 (94.6%) 91/101 (90.1%) .140 Age 1.03 (1.01-1.04) .003
MASP2_120 (TC) 12/221 (5.4%) 10/101 (9.9%)  MELD score 1.11 (1.08-1.14) <.001
FCN2B_6359 (CC) 123/226 (54.4%) 44/101 (43.6%) .023 MBL_Yx (GC/CC vs GG) 1.72 (1.15-2.57) .008
FCN2B_6359 (CT) 79/226 (35.0%) 51/101 (50.5%)  MASP2_371 (AC/CC vs AA) 1.67 (1.12-2.49) .012
FCN2B_6359 (TT) 24/226 (10.6%) 6/101 (5.9%)  NOD2_G908R (GC vs GG) 2.78 (1.74-4.44) <.001
FCN2_4 (AA) 118/223 (52.9%) 48/102 (47.1%) .067    
FCN2_4 (AG) 84/223 (37.7%) 50/102 (49.0%)     
FCN2_4 (GG) 21/223 (9.4%) 4/102 (3.9%)     
MASP2_371 (AA) 148/221 (67.0%) 54/100 (54.0%) .012    
MASP2_371 (AC) 57/221 (25.8%) 42/100 (42.0%)     
MASP2_371 (CC) 16/221 (7.2%) 4/100 (4.0%)     
MBL_Yx (GG) 142/223 (63.7%) 51/102 (50.0%) .056    
MBL_Yx (GC) 71/223 (31.8%) 43/102 (42.2%)     
MBL_Yx (CC) 10/223 (4.5%) 8/102 (7.8%)     
NOD2_R702W (CC) 193/221 (87.3%) 95/100 (95.0%) .036    
NOD2_R702W (CT) 28/221 (12.7%) 5/100 (5.0%)     
NOD2_G908R (GG) 219/221 (99.1%) 92/100 (92.0%) .002    
NOD2_G908R (GC) 2/221 (0.9%) 8/100 (8.0%)     
Note: In univariate analysis only SNPs with P-value < .2 are presented, which were included in the multivariate analysis. Liver transplantation as 
competing risk in multivariate analysis of mortality. Age and MELD score were taken as independent variables.
TA B L E  4   Univariate and multivariate analysis - risk for acute bacterial infection in all patients
Univariate analysis Multivariate analysis
 
No bacterial 
infection Bacterial infection P-value  OR (95% CI) P-value
FCN2B_6424 (GG) 387/471 (82.2%) 251/328 (76.5%) .051 CLIF-C OF score 1.61 (1.44-1.81) <.001
FCN2B_6424 (GT/TT) 84/471 (17.8%) 77/328 (23.5%)  WBC 1.07 (1.03-1.11) <.001
MBL_Hl (GG) 193/466 (41.4%) 141/325 (43.4%) .187 Prophylactic antibiotic for SBP 0.45 (0.26-0.77) .004
MBL_Hl (GC) 222/466 (47.6%) 137/325 (42.2%)   
MBL_Hl (CC) 51/466 (10.9%) 47/325 (14.5%)  
Note: In univariate analysis only SNPs with P-value < .2 are presented, which were included in the multivariate analysis. In the multivariate logistic 
regression model CLIF-C score, WBC and prophylactic use of AB were taken as independent variables.
Abbreviations: CLIF-C OF, organ failure score for acute-on-chronic liver failure; SBP, spontaneous bacterial peritonitis; WBC, white blood cell.
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and bacterial infection and mortality have been subject of previous 
studies, showing conflicting results. Appenrodt et al20 found in 150 
patients with cirrhosis and ascites that carriers of common NOD2 
genetic variants had a significantly reduced survival in comparison to 
patients with wildtype genotypes. Bruns et al (n = 175)25 and Dinya 
et al (n = 349)26 subsequently studied this association, however no 
significant association between common NOD2 genetic variants and 
higher risk of mortality was observed. In our study, the sample size 
was sufficient to perform the survival analysis for each NOD2 genetic 
variant individually, whereas in other studies the carrier status for any 
NOD2 genetic variant was pooled in the analysis. Interestingly, we 
found that both NOD2-R702W and NOD2-L1007FSINSC were not 
associated with increased mortality whereas NOD2-G908R was asso-
ciated with worse survival independently of age and MELD score. This 
finding may explain that no effect of NOD2 genetic variants on mor-
tality was reported in the studies of Bruns and Dinya, since all NOD2 
genetic variants were pooled together in those survival analyses.25,26 
Another explanation for the difference in findings regarding survival 
could be that Appenrodt et al and our study had a relatively short fol-
low-up time, in contrast to the longer follow-up periods of the stud-
ies of Bruns and Dinya. It is likely that after a longer follow-up period 
other factors such as (de)compensated end-stage liver failure or other 
organ failures may have more impact on the survival, whereas in the 
short term the innate immunity genetic variant has a negative impact 
on survival, particularly in patients with an acute bacterial infection.
In patients after liver transplantation, our group17 found that single 
nucleotide polymorphisms in the MBL, MASP and FNC2 genes were 
major determinants for the occurrence of clinically significant bac-
terial infection and mortality. Furthermore, various studies showed 
that functional deficiencies of MBL, FNC and MASP serum protein 
levels lead to increased risk of bacterial infection in patients with cir-
rhosis.14,15 In our study we did not confirm that the genetic profile of 
the lectin pathway of complement activation had a major impact on 
the occurrence of bacterial infection in patients with decompensated 
cirrhosis. Serum protein levels of lectin pathway molecules were not 
determined in our study, therefore we could not assess if presence of 
a genetic variant correlated with clinically relevant deficiency of these 
molecules. However, NOD2-G908, MBL_Yx and MASP2_371 genetic 
variants were associated with a significantly higher short-term mortal-
ity in patients with an acute bacterial infection. The NOD2-G908 gene 
variant has previously been shown to be associated with increased 
translocation of bacterial DNA fragments in ascitic fluid in patients 
with culture-positive SBP.24,27 These studies support the functional 
relevance of this single nucleotide polymorphism. It may be hypoth-
esized that these genetic variants are associated with a more severe 
clinical course in the presence of bacterial infection, rather than af-
fecting the susceptibility of developing a bacterial infection. However, 
our study does not permit a conclusion in that respect. There were 
many missing data with regard to the presence of sepsis and systemic 
inflammatory response syndrome, which may be considered as mark-
ers of more severe outcome. Moreover, there were no data available in 
the CANONIC database with regard to primary cause of death or the 
presence or absence of bacterial infection at time of death.
The studies of Appenrod et al20 and Bruns et al25 reported strong 
associations between pooled NOD2 genetic variants and the pres-
ence of SBP in patient cohorts with comparable disease severity as 
expressed by the Child-Pugh score and MELD score. In this study we 
could not confirm these findings, however there are several poten-
tial explanations for this discrepancy. Firstly, the prophylactic intake 
of antibiotics varied between the cohorts although to which extend 
this influenced the outcome cannot be determined. Secondly, no pro-
tocol-driven diagnostic paracentesis was performed for our study, 
therefore potentially some SBP cases may have been missed. Finally, 
the approach we used by analysing the different NOD2 single nucle-
otide polymorphisms separately may account for absence of associa-
tion between SBP and NOD2 SNPs. In a recent study in patients with 
compensated cirrhosis, pooled NOD2 genetic variants were found to 
be a risk factor for the occurrence of bacterial infections but not in a 
subgroup of patients with decompensated cirrhosis.28 This suggests 
that NOD2 genetic variants have an impact on susceptibility to bacte-
rial infection in compensated cirrhosis and other factors may be more 
relevant in decompensated cirrhosis.
Strengths of this study were the large cohort of patients from 
different European centres which allowed us to study genetic vari-
ants individually and combined, the vigorous and uniform prospec-
tive collection of clinical data and blinding of the authors for clinical 
outcomes during genotyping of the SNPs. Limitations of this study 
were the testing of selected SNPs with known functional relevance, 
whereas an unbiased approach may provide new insights and the 
lack of information about bacterial infections occurring more than 
3 months preceding inclusion in this study.
In conclusion, NOD2-G908R, MASP2_371 and MBL_Yx genetic vari-
ants were found to be independently associated with increased risk of 
short-term mortality in cirrhotic patients with decompensated cirrhosis or 
ACLF, particularly in those with bacterial infections. Functionally relevant 
polymorphisms in the lectin complement pathway and innate immune 
signalling components for pathogen recognition were not associated with 
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increased occurrence of a bacterial infection or SBP alone. Further stud-
ies are required to address whether a personalized approach based on 
innate immunity genetic variants could improve survival. A well-designed 
randomized clinical trial should be performed in order to define whether 
antibiotic prophylaxis would be beneficial for cirrhotic patients with ge-
netic variants at risk for acute bacterial infection.
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